Metformin (Met) is the most commonly used glucose-lowering agent for patients with type 2 diabetes (T2D) primarily because of its ability to suppress hepatic gluconeogenesis via an adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK)-dependent mechanism [12,13]. Here, WEE1 is linked to type 2 diabetes mellitus.